Posted from: Thursday, May 05, 2016 - 12:22 PM - Present

Gilotrif Approved for Lung Cancer Treatment

April 15, 2016 – Gilotrif® (afatinib) received FDA approval for the treatment of those with metastatic squamous non-small cell lung cancer (NSCLC). Manufactured by Boehringer Ingelheim, Gilotrif is for patients whose disease has progressed after treatment with platinum-based chemotherapy. Originally approved in July 2013, Gilotrif is a kinase inhibitor for patients with metastatic NSCLC and whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations. Supplied as 20mg, 30mg, and 40mg tablets, the recommended dose for each indication is 40mg once daily.

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Wednesday, October 16, 2019 - 03:57 PM.